

31. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. *Am J Transplant.* 2008;8:984–989.
32. Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. *Radiographics.* 2007;27:145–159.
33. Marques HH, Shikanai-Yasuda MA, de Azevedo LSF, et al. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients. *Rev Soc Bras Med Trop.* 2014;47:543–546.
34. Emmott J, Sanghera B, Chambers J, Wong WL. The effects of N-butylscopolamine on bowel uptake: an ^{18}F -FDG PET study. *Nucl Med Commun.* 2008;29:11–16.
35. Montes HH, de Jesus FM, Kwee TC, Nijland M, et al. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: a systematic review and meta-analysis. *Crit Rev Oncol Hematol.* 2018;132:27–38.
36. Bhat M, Mara K, Dierkhising R, Watt KDS. Immunosuppression, race, and donor-related risk factors affect de novo cancer incidence across solid organ transplant recipients. *Mayo Clin Proc.* 2018;93:1236–1246.
37. Adams HJA, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. *Eur J Radiol.* 2016;85:1963–1970.

Erratum

In the article “ ^{11}C -PBR28 and ^{18}F -PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis,” by Datta et al. (*J Nucl Med.* 2017;58:1477–1482), the name of one of the authors was misspelled. “Nicola D. Stefano” should be “Nicola De Stefano.” The authors regret the error.